Bisphosphonates
The majority of myeloma patients have regular treatment with bisphosphonates during their disease course. This guide has information on the drugs used, why they are important, and nursing management of side effects.
DetailsThe majority of myeloma patients have regular treatment with bisphosphonates during their disease course. This guide has information on the drugs used, why they are important, and nursing management of side effects.
DetailsThe Scottish Referral Guidelines for Suspected Cancer were created to help GPs, the wider primary care team, other clinicians, patients and carers to identify those people who are most likely to have cancer and who therefore require urgent assessment by a specialist. Equally, it is hoped that the guidelines will help clinicians to identify people…
DetailsFrom March until May 2022 Myeloma UK ran a campaign highlighting the importance of a timely myeloma diagnosis.
Read about the report on the impact of delayed diagnosis and the diagnosis-focused research programme launched during the campaign.
Myeloma UK presented a poster at the 62nd Annual Scientific Meeting of the British Society for Haematology 2022.
The poster summarised data collected from patient surveys as part of the Clinical Service Excellence Programme (CSEP) accreditation process. Read more to learn what patients would change if they could change one thing about their myeloma treatment and care.
In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease.
We are pleased to report that University College London Hospital, Leicester Royal Infirmary, Basingstoke and North Hampshire Hospital, Dorset County Hospital and Salisbury District Hospital have all received Myeloma UK’s CSEP award. Each hospital has demonstrated excellent clinical practice, with some notable highlights.
Details